scholarly journals Understanding the role of serum lactate as an end point in burn resuscitation

2020 ◽  
Vol 28 (1) ◽  
pp. 7
Author(s):  
AbhaRani Kujur ◽  
NitaTrina D′souza ◽  
D Rajeswari
Keyword(s):  
Serum Lactate ◽  
End Point ◽  
Burn Resuscitation

scholarly journals β-Arrestin-1 expression and epithelial-to-mesenchymal transition in laryngeal carcinoma

2019 ◽  
Vol 34 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Gino Marioni ◽  
Lorenzo Nicolè ◽  
Rocco Cappellesso ◽  
Rosario Marchese-Ragona ◽  
Elena Fasanaro ◽  
...  
Keyword(s):  
Epithelial To Mesenchymal Transition ◽  
Disease Free Survival ◽  
The Novel ◽  
Free Survival ◽  
Mesenchymal Transition ◽  
End Point ◽  
Zeb2 Expression ◽  
E Cadherin

Aim: The novel primary end-point of the present study was to ascertain β-arrestin-1 expression in a cohort of consecutive patients with laryngeal squamous cell carcinoma (LSCC) with information available on their cigarette-smoking habits. A secondary end-point was to conduct a preliminary clinical and pathological investigation into the possible role of β-arrestin-1 in the epithelial-to-mesenchymal transition (EMT), identified by testing for E-cadherin, Zeb1, and Zeb2 expression, in the setting of LSCC. Methods: The expression of β-arrestin-1, E-cadherin, zeb1, and zeb2 was ascertained in 20 consecutive LSCCs. Results: Statistical analysis showed no significant associations between β-arrestin-1 and EMT (based on the expression of E-cadherin, Zeb1, and Zeb2). The combined effect of nicotine and β-arrestin-1 was significantly associated with a shorter disease-free survival ( P=0.01) in our series of LSCC. This latter result was also confirmed in an independent, publicly available LSCC cohort ( P=0.047). Conclusions: Further investigations on larger series (ideally in prospective settings) are needed before we can consider closer follow-up protocols and/or more aggressive treatments for patients with LSCC and a combination of nicotine exposure and β-arrestin-1 positivity in tumor cells at the time of their diagnosis. Further studies on how β-arrestin functions in cancer via different signaling pathways might reveal potential targets for the treatment of even advanced laryngeal malignancies.

scholarly journals The Role of Platinum Based Chemotherapy in Neoadjuvant Treatment of Locally Advanced Triple Negative Breast cancer

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
H M Abdelaziz ◽  
D R Diab ◽  
A M Adel ◽  
M Y Mostafa ◽  
M M Gaddalla
Keyword(s):  
Breast Cancer ◽  
Clinical Oncology ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Phase Iii ◽  
End Point ◽  
Platinum Based Chemotherapy

Abstract Background The treatment of patients with TNBC is the biggest challenge in the breast cancer (BC) scenario. TNBC remains the poorest prognosis breast cancer (BC) subtype, usually high-grade tumors with higher incidence of visceral and cerebral metastases. Cytotoxic chemotherapy is the backbone of triple-negative breast cancer treatment. Objective A phase III prospective study designed to investigate the role of addition the platinum based chemotherapy to the neoadjuvant setting in treatment of locally advanced triple negative breast cancer, Considering pathological response, complete (pCR) and partial (pPR) as a primary end point, and toxicity, disease free survival as a secondary end point. Patients and Methods This study was a phase III prospective one. 51 female patients Included with locally advanced triple negative Breast Cancer referred to Clinical Oncology& Radiotherapy Department, AIN SHAMS University Hospitals. Results A total of 51 female patients between ages 23-73 years with median age was 45 years old and with locally advanced features of breast cancer, (stage IIIa-IIIb-IIIc) were enrolled in the study during a recruiting period from October 2013 till October 2017 at Ain Shams University, clinical oncology department. Six patients (11.8%) were excluded from the analysis after enrollment, they didn’t receive neoadjuvant treatment because they underwent surgery or they developed metastasis So, only 45 patients received the neoadjuvant treatment. The median follow-up duration was 19 months after surgery. Conclusion Clearly, there were no statistical significance neither survival benefit in addition of the platinum to the NST comparison with the classic anthracyclines + taxens treatment. Even there was more clinical regression with platinum, but more recurrence and relapse occurred. There for, there is a major need to better understand the characteristics and the clinical behavior of TNBCs with an aim to develop effective treatments for this BC subtype.

Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3115-3115
Author(s):  
Krina Patel ◽  
Robert Z. Orlowski ◽  
Nina Shah ◽  
Qaiser Bashir ◽  
Simrit Parmar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Stem Cell ◽  
Lactate Dehydrogenase ◽  
Hematopoietic Stem Cell Transplantation ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Hematopoietic Stem ◽  
The Impact

Abstract Abstract 3115 Background: The International Staging System (ISS), chromosomal abnormalities, and response to therapy are well recognized predictors of outcome in multiple myeloma (MM). However, the role of serum lactate dehydrogenase (LDH) as a prognostic marker for MM is not well established. Recently we showed that high LDH at diagnosis of MM is a predictor of shorter survival. Here we report the impact of the LDH level at the time of autologous hematopoietic stem cell transplantation (auto-HCT) on its outcome. Methods: We evaluated 1,658 patients with symptomatic myeloma who underwent auto-HCT from July 1988 to December 2010 at our institution. The primary objective was to determine the impact of high LDH (>1000 IU/L) level, obtained on the start day of the preparative regimen, on progression free survival (PFS) and overall survival (OS). Results: Patient characteristics according to LDH level at auto-HCT are summarized in Table 1. Patients in the 2 LDH groups (>1000 or ≤ 1000) were matched for age, gender, disease status, and response to prior therapy at the time of auto-HCT. Patients with LDH >1000 IU/L had a significantly higher beta-2 microglobulin (β2m) and bone marrow plasmacytosis at the time of auto-HCT. Median times to neutrophil (10 vs. 10 days: p=0.10) and platelet engraftment (11.3 vs.12.2 days: p=0.20) were not different in the 2 groups. Also, there was no significant difference in CR, VGPR, PR or overall response rates between the 2 groups. Median follow up was 35 months (1 to 244). Median OS in patients with LDH >1000 and ≤ 1000 were 49.2 and 68.0 months, respectively (p=0.03). Median PFS in patients with LDH >1000 and ≤ 1000 were 14.4 and 24.7 months, respectively (p=0.001). On univariate analyses, >10% plasma cells in bone marrow biopsy, relapsed disease, serum β2M ≥ 3.5 at auto-HCT, presence of any chromosomal abnormality, and < PR after auto-HCT were associated with significantly shorter PFS and OS. Conclusions: Having a serum LDH value of >1000 IU/L prior to auto-HCT is associated with shorter PFS and OS in patients with MM. These high risk patients may require aggressive post-transplant therapy, including consolidation, maintenance, tandem transplants or novel approaches like immunotherapy. Disclosures: Shah: Celgene: Membership on an entity's Board of Directors or advisory committees.

The Role of Albumin in Burn Resuscitation

1981 ◽  
Vol 2 (5) ◽  
pp. 290 ◽  
Author(s):  
William W. Monafo
Keyword(s):  
Burn Resuscitation

Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells

2012 ◽  
Vol 71 (3) ◽  
pp. 635-645 ◽  
Author(s):  
Samy A. F. Morad ◽  
Maria C. Messner ◽  
Jonathan C. Levin ◽  
Noha Abdelmageed ◽  
Hyejung Park ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Potential Role ◽  
Acid Ceramidase ◽  
End Point ◽  
Pancreatic Cancer Cells

scholarly journals Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma

2013 ◽  
Vol 130 (4) ◽  
pp. 305-311 ◽  
Author(s):  
Junshik Hong ◽  
Hyun-Hwa Yoon ◽  
Hee Kyung Ahn ◽  
Sun Jin Sym ◽  
Jinny Park ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Prognostic Role ◽  
Large B Cell Lymphoma ◽  
Large B Cell

CXCR4 is a prognostic marker in acute myelogenous leukemia

Blood ◽  
2006 ◽  
Vol 109 (2) ◽  
pp. 786-791 ◽  
Author(s):  
Anke C. Spoo ◽  
Michael Lübbert ◽  
William G. Wierda ◽  
Jan A. Burger
Keyword(s):  
Acute Myelogenous Leukemia ◽  
Chemokine Receptors ◽  
Serum Lactate ◽  
Cxcr4 Expression ◽  
Myelogenous Leukemia ◽  
Serum Lactate Dehydrogenase ◽  
Fluorescence Intensity Ratio ◽  
Acute Myelogenous ◽  
Univariate Analyses

Abstract CXCR4 chemokine receptors retain hematopoietic progenitors and leukemia cells within the marrow microenvironment. We prospectively evaluated the prognostic implication of CXCR4 in 90 consecutive patients with acute myelogenous leukemia (AML) by flow cytometry. Patients were divided into groups with low (n = 32), intermediate (n = 26), or high (n = 32) CXCR4 expression, as defined by CXCR4 mean fluorescence intensity ratio thresholds of less than 5, 5 to 10, or more than 10, respectively. We found that low CXCR4 expression on AML cells correlated with a better prognosis, resulting in a longer relapse-free and overall survival of 24.3 ± 2.9 months for low CXCR4-expressing patients, compared with 17.4 ± 3.4 months for intermediate and 12.8 ± 2 months (mean ± SEM) for patients with high expression. In univariate analyses, CXCR4 expression, cytogenetics, white blood cell count, and serum lactate dehydrogenase (LDH) predicted for shorter survival. Multivariate analysis revealed CXCR4 expression and unfavorable cytogenetics as independent prognostic factors. We conclude that CXCR4 expression in AML is an independent prognostic predictor for disease relapse and survival that can rapidly and easily be determined at disease presentation. These findings warrant further investigation into the role of CXCR4 in AML and suggest that CXCR4 should be incorporated into the risk assessment of AML patients.

Sign in / Sign up

Export Citation Format

Share Document